Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Kenta Baba

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0002-2179-552X; OpenAlex author ID A5101083680. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2023: 1 paper · 2024: 3 papers · 2025: 1 paper · 2026: 3 papers

Papers 8

  1. Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential tyrosine receptor kinase inhibitors. Co-author DOI 10.1007/s12328-026-02388-z↗
  2. TMPRSS4 Expression Predicts Survival and Benefit from Neoadjuvant Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20228-9↗
  3. ASO Visual Abstract: TMPRSS4 Expression Predicts Survival and Benefit From Neoadjuvant Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20329-5↗
  4. Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12898↗
  5. Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer with arterial contact: Results from a ph… Co-author DOI 10.1002/jhbp.1412↗
  6. Δ3-tubulin impairs mitotic spindle morphology and increases nuclear size in pancreatic cancer cells. Co-author DOI 10.1007/s00795-023-00373-w↗
  7. Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15221-z↗
  8. Prognostic factor in patient with recurrent pancreatic adenocarcinoma. Co-author DOI 10.1007/s00423-023-03073-2↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenichiro Uemura · 6 shared papers, 2023–2026 · strength 1.36
  2. Tatsuaki Sumiyoshi · 5 shared papers, 2023–2026 · strength 1.10
  3. Shin’ya Takahashi · 5 shared papers, 2023–2025 · strength 1.07
  4. Takeshi Sudo · 4 shared papers, 2024–2026 · strength 1.00
  5. Yoshiaki Murakami · 4 shared papers, 2023–2025 · strength 0.81
  6. Kenjiro Okada · 4 shared papers, 2023–2025 · strength 0.81
  7. Ryuta Shintakuya · 4 shared papers, 2023–2025 · strength 0.81
  8. Yosuke Shimizu · 3 shared papers, 2026 · strength 0.79
  9. Shinya Takahashi · 3 shared papers, 2026 · strength 0.79
  10. Hirotaka Tashiro · 3 shared papers, 2026 · strength 0.79
  11. Takumi Harada · 3 shared papers, 2024–2025 · strength 0.65
  12. Yasutaka Ishii · 3 shared papers, 2023–2025 · strength 0.60
  13. Sho Tazuma · 1 shared paper, 2026 · strength 0.29
  14. Koji Ikegami · 1 shared paper, 2024 · strength 0.26
  15. Shiro Oka · 1 shared paper, 2025 · strength 0.25
  16. Naru Kondo · 1 shared paper, 2024 · strength 0.21
  17. Shinya Nakamura · 1 shared paper, 2024 · strength 0.20
  18. Hiroyuki Otsuka · 1 shared paper, 2023 · strength 0.16
  19. Tomofumi Tsuboi · 1 shared paper, 2023 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.